Immune function marker does not predict benefit of trastuzumab in HER-2+...
And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in...
View ArticleNew breast cancer classification based on epigenetics
The identification of patients with high-risk breast cancer is key to knowing whether a patient will require only the removal of the tumor by surgery or whether if she will need additional chemotherapy...
View ArticleImmune function marker does not predict benefit of trastuzumab in HER-2+...
And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in...
View ArticleTamoxifen reduces breast cancer rates by nearly a third for 20 years —...
The IBIS-I trial (International Breast Cancer Intervention Study), led by Queen Mary University of London and funded by Cancer Research UK, examined the long-term risks and benefits of taking tamoxifen...
View ArticleTamoxifen reduces breast cancer rates by nearly a third for 20 years
The IBIS-I trial (International Breast Cancer Intervention Study), led by Queen Mary University of London and funded by Cancer Research UK, examined the long-term risks and benefits of taking tamoxifen...
View ArticleDiagnostic tool Oncotype DX associated with reduction in chemotherapy rates...
Mariana Chavez Mac Gregor, M.D., assistant professor, health services research and breast medical oncology, will present the findings at a poster session of the 2014 San Antonio Breast Cancer...
View ArticleBreast density helps better predict breast cancer risk — ScienceDaily
The study, "Volumetric Breast Density Improves Breast Cancer Risk Prediction," was presented during the 2014 San Antonio Breast Cancer Symposium. "There is increasing interest in implementing...
View ArticlePalbociclib shows promise in patients with hormone-resistant breast cancer
"The FDA approval has expanded treatments options for many metastatic breast cancer patients, but these new results are showing how effective the drug can also be for breast cancer patients who have...
View ArticleWomen back idea of more breast screens for those at high risk of cancer
Fewer women (60 per cent) would be happy to be screened less often if they were found to be at lower risk. More than 940 women from across the UK were asked for their views on the possibility of...
View ArticleAnderson algorithm increases surgical success with advanced ovarian cancer
The researchers describe the Anderson Algorithm in a perspective piece outlining a personalized surgical approach to ovarian cancer published online at Nature Reviews Clinical Oncology. "Our algorithm...
View Article
